Verrica issues statement in support of FDA’s letters on treatment of MC

Verrica Pharmaceutical issued a statement in support of the U.S. Food and Drug Administration’s, FDA, recent action against retailers and manufacturers of unapproved products for the treatment of molluscum contagiosum, MC. “On the heels of the June 1, 2023 FDA warning to consumers not to use unapproved products for the treatment of molluscum contagiosum, we are pleased the FDA is taking additional measures against these unapproved products,” said Ted White, President and Chief Executive Officer of Verrica Pharmaceuticals. “It is clear that the FDA views molluscum as a serious health problem that requires medical intervention with therapies that have been rigorously tested and properly reviewed. Verrica has conducted two Phase 3 trials to demonstrate the clinical safety and efficacy of YCANTH, so that the millions of people, primarily children, who suffer from this viral infection can finally receive a safe, effective, and FDA-approved treatment for their condition.”